Depakote ER in Bipolar Depression

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.

Clinical Trial Description

Mood disorders are important public health problems. Bipolar disorder is a major psychiatric disorder characterized by mood cycles alternating between mania and depression and affects approximately 1% of the population. Most patients are treated beginning in the early twenties and then embark on a course marked by multiple recurrences, hospitalizations, and encounters with legal authorities. These disorders inflict substantial morbidity which yields important deficits in occupational and interpersonal function. The risk of suicide in mood disorders may be as high as 10%.

Although the outlook for recovery from acute manic or depressive episodes is generally excellent, the long-term prognosis of the disorder varies tremendously across the patient population. The introduction of lithium, anticonvulsants and atypical antipsychotics significantly changes the outlook for bipolar disorder, with some individuals on chronic treatment attaining complete remission and indefinite prophylaxis against mood episodes. However, such optimum outcomes may be limited to as few as one-third to one-half of all treated patients. The remaining experiences various combinations of breakthrough mood episodes, including chronic mood instability, persistent depression, and rapid cycling.

Very little research has been conducted with bipolar disorder, and no medications have an FDA indication to treat bipolar depression. Previous studies suggest that Depakote is promising in the treatment of mixed and depressed episodes of bipolar disorder. This study utilizes the extended release formulation of divalproex sodium, with demonstrated increased tolerability.

We propose investigating safety, tolerability and efficacy of Depakote ER monotherapy in Bipolar I, II or NOS depression, and monitoring associated changes in brain GABA levels. In addition, we intend to evaluate and assess the differences between brain metabolic rate and GABA levels in bipolar disorder patients and healthy volunteers. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00186186
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Phase 4
Start date	January 2004
Completion date	January 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Not yet recruiting	`NCT05958940` - BioClock: Bright Light Therapy for Depressive Disorders	N/A
Recruiting	`NCT02919280` - Dallas 2K: A Natural History Study of Depression
Completed	`NCT00060489` - Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression	Phase 3
Recruiting	`NCT05767073` - LIVES: Personalized Lifestyle Intervention for Patients With Depression	N/A
Completed	`NCT04121091` - Pramipexole to Target "Anhedonic Depression"	Phase 2
Recruiting	`NCT04057378` - Optimal Electrical Stimulus During Electroconvulsive Therapy	Phase 4
Completed	`NCT03287037` - The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression	N/A
Completed	`NCT00483548` - Adjunctive Ziprasidone in the Treatment of Bipolar I Depression	Phase 3
Not yet recruiting	`NCT05568823` - Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder	N/A
Completed	`NCT00191399` - Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response	Phase 4
Recruiting	`NCT05436613` - Transcranial Direct Current Stimulation Therapy for Bipolar Depression	N/A
Completed	`NCT03538275` - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Recruiting	`NCT04846010` - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2	Phase 1/Phase 2
Withdrawn	`NCT02625779` - Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression	Phase 2
Recruiting	`NCT02778256` - Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder	N/A
Active, not recruiting	`NCT04643210` - Management of my Bipolarity Intervention in Bipolar Disorder Patients	N/A
Completed	`NCT01396447` - Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression	Phase 2
Enrolling by invitation	`NCT02827045` - Study of a Vestibular Biomarker of Phase in Bipolar Disorder
Completed	`NCT01898429` - Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.